Diet/Lifestyle Strategies for Preventing Benign Prostatic Hyperplasia

McCarty, Mark F.

doi:10.4172/2167-0943.s1-e001

Cited by 3 publications

(4 citation statements)

References 78 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…30 Recently, healthy diet and lifestyles have been considered as optimal strategies to prevent BPH. 38 In the present study, our finding reflects that metformin is a useful medicine for BPH patients in reducing prostate cancer risk. Cancer prevention of metformin is effective through the mechanism by decreasing hyperinsulinemia-associated carcinogenesis.…”

Section: Discussionsupporting

confidence: 67%

“…Many interventions are effective in relieving these symptoms, such as alpha blockers, 5‐alpha reductase inhibitors, transurethral resection of the prostate and laser‐based surgeries . Recently, healthy diet and lifestyles have been considered as optimal strategies to prevent BPH . In the present study, our finding reflects that metformin is a useful medicine for BPH patients in reducing prostate cancer risk.…”

Section: Discussionsupporting

confidence: 67%

See 1 more Smart Citation

Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

et al. 2019

View full text Add to dashboard Cite

Benign Prostate Hyperplasia (BPH) has been associated with prostate cancer prevalent among men after 50 years of age, however, it is unclear whether the antidiabetic drug, metformin, can reduce prostate cancer for men with BPH. The insurance claims data of men aged 50 years or older, with both type 2 diabetes mellitus (T2DM) and BPH diagnosed from 1997 to 2007 were analyzed. Individuals were followed up for at least 5 years. We identified 2906 and 2906 patients as the metformin cohort and nonmetformin cohort, respectively. The Cox method analysis showed that the metformin cohort had an adjusted hazard ratio (aHR) of 0.69 (95% confidence interval [CI] = 0.49‐0.96, P = 0.0298) for prostate cancer, compared to the nonmetformin cohort after controlling for age, traditional Chinese medicine (TCM) use, prostate specific antigen, and Charlson comorbidity index. Patients using TCM for BPH (per 6 months) also had an aHR of 0.41 (95% CI = 0.24‐0.69; P = 0.0009). In conclusion, both metformin medication and TCM use could be associated with reduced risk of prostate cancer for men with BPH and diabetes.

show abstract

Section: Discussionsupporting

confidence: 67%

Section: Discussionsupporting

confidence: 67%

Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…A hypothesis about the association between insulin resistance and benign prostatic hyperplasia is based on the mechanism where the increased levels of insulin result in insulin resistance and thus increased levels of insulin-like growth factors (IGF 1). This is followed by the inhibition of hepatic secretion of insulin-like growth factor binding protein (IGFBP-1), an IGF 1 antagonist [ 57 ]. The reduced IGF 1 level within the prostate promotes prostate cell proliferation [ 58 ].…”

Section: Discussionmentioning

confidence: 99%

Can Metabolic Disorders in Aging Men Contribute to Prostatic Hyperplasia Eligible for Transurethral Resection of the Prostate (TURP)?

Rył

Rotter

Słojewski

et al. 2015

IJERPH

View full text Add to dashboard Cite

Purpose: The aim of this study was to evaluate the incidence and severity of metabolic disorders occurring in the metabolic syndrome in patients with benign prostatic hyperplasia eligible for surgical treatment. Methods: The study group consisted men with diagnosed benign prostatic hyperplasia. The control group consisted patients recruited from basic health care units. Abdominal circumference, body weight and blood serum metabolic parameters were determined in the experimental and control groups. The concentrations of glucose were determined, as well as total cholesterol (ChT), low-density lipoprotein (LDL), high density lipoprotein (HDL) and triglycerides (TAG), by spectrophotometric method using reagent kits. Results: In the study group 91 (60.3%) cases of metabolic syndrome (MetS) were diagnosed, while in the control group 71 (46.1%) men met the diagnostic criteria for this syndrome (p = 0.018). The analysis shows a relationship between MetS in patients with BPH and concentration glucose, ChT, LDL, HDL, systolic blood pressure and diastolic blood pressure. We found no significant statistical relationship between body weight, abdominal circumference and concentration TAG, hypertension in patients and controls. Conclusions: in the study presented in this article, statistically significant relationships between BPH and the diagnostic parameters of the metabolic syndrome were demonstrated. These results indicate to the necessity of the modification of the lifestyle, taking preventive measures in diabetes, and evaluation of lipid metabolism disorders. It is recommended to assess symptoms that may suggest BPH (as a manifestation of LUTS) in men over 50 years of age with diagnoses of metabolic disorders (including MetS), and provide them with specialist urological care in order to prevent surgical treatment of the prostate.

show abstract

“…The pathophysiology of MetS is controversial and is not yet completely determined but it is mainly attributed to insulin resistance and central obesity [37,87,88]. The relationship between insulin resistance and central obesity is complex [89,90]. Both of them lead to subsequent metabolic risk factors, particularly hyperglycemia, dyslipidemia, and hypertension that predispose to T2DM and CVD [30,90,91].Other contributory factors include genetic or ethnic predisposition, aging, physical inactivity, high caloric intake, cigarette smoking, Western-style diet, proinflammatory state, and hormonal imbalance [92,93].…”

Section: Metabolic Syndrome: Pathophysiologymentioning

confidence: 99%

Developmental Trends of Metabolic Syndrome in the Past Two Decades: A Review

Obeidat,

Ghabashi,

Alazzeh

et al. 2024

Preprint

View full text Add to dashboard Cite

Abstract Background: Metabolic syndrome (MetS) is a complex disorder characterized by insulin resistance (IR), central obesity, atherogenic dyslipidemia and higher glucose levels. It increases the risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM), imposing an economic burden on the healthcare system. However, the historical origins of MetS as well as the development and evolution of its definitions have not been conclusively documented in the literature. Aim: This study seeks to enhance the understanding of the developmental trends of MetS during the preceding two decades, placing particular emphasis on the definition, diagnosis and prevalence. Methods: An extensive search was performed from 1920 to 2023 across prominent scientific research engines, including Scopus, PubMed, MDPI, and others. Results: Despite advancements, many aspects of MetS remain inadequately understood. As the understanding of the nature and pathophysiology of MetS progresses, the development and refinement of its diagnostic criteria, and assessment and treatment guidelines will continue. Additionally, there exists significant variation in the global prevalence of metabolic syndrome, ranging from 14 to 39%. This prevalence is projected to increase due to the adoption of less healthy dietary patterns and sedentary lifestyles. The observed disparities in metabolic syndrome prevalence can be attributed to multiple factors, including demographic characteristics. Furthermore, the lack of a standardized definition across studies also contributes to the variation in reported prevalence rates. Conclusion: Further studies focusing on the standardization of the MetS definition across different research are crucial. The establishment of consistent criteria would enhance the reliability and validity of research findings, enabling more meaningful comparisons and interpretations.

show abstract

Diet/Lifestyle Strategies for Preventing Benign Prostatic Hyperplasia

Abstract: Journal of Metabolic Syndrome Journ a l o f M et abol ic S y n d ro me

Cited by 3 publications

References 78 publications

Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

Metformin reduces prostate cancer risk among men with benign prostatic hyperplasia: A nationwide population‐based cohort study

Can Metabolic Disorders in Aging Men Contribute to Prostatic Hyperplasia Eligible for Transurethral Resection of the Prostate (TURP)?

Developmental Trends of Metabolic Syndrome in the Past Two Decades: A Review

Contact Info

Product

Resources

About